The current lead plaintiffs in the Cyberonics, Inc. securities litigation are looking for some help.
According to a press release issued on Monday, the lead plaintiff process in the case has been reopened, nearly 15 months after the original lead plaintiffs were appointed.
Curiously, the announcement comes after a prior consolidated amended complaint was dismissed, and four months after the first amended complaint was filed. A copy of the first amended complaint is available from Stanford, here.
The new complaint substantially expands the class period and adds allegations related to options backdating.
The Cyberonics litigation is pending in the United States District Court Southern District Of Texas before Judge Gray H. Miller.
EFCAT, Inc., John E. and Cecilia Catogas, Blanca Rodriguez and Mohamed Bakry are the current lead plaintiffs in the Cyberonics litigation and Finkelstein & Krinsk LLP and Scott + Scott LLC are currently serving as co-lead counsel.
Daily Trivia: Cyberonic's only product is an implantable medical device for the long-term treatment of epilepsy, depression, and other chronic disorders using vagus nerve stimulation therapy.
The vagus nerve is the only nerve that starts in the brainstem and extends down below the head, to the abdomen. It is also known as the "pneumogastric nerve since it innervates both the lungs and the stomach." The name is derived from the Latin word vagus, literally meaning "wandering."